Acrux Limited (ASX:ACR)

Market Cap	4.52M -64.9%
Revenue (ttm)	2.81M +250.4%
Net Income	-2.36M
EPS	-0.01
Shares Out	410.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191,841
Average Volume	276,047
Open	0.0110
Previous Close	0.0110
Day's Range	0.0110 - 0.0110
52-Week Range	0.0110 - 0.0270
Beta	0.93
RSI	38.13
Earnings Date	May 25, 2026

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 43
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACR

Financial Performance

In fiscal year 2025, Acrux's revenue was 1.19 million, a decrease of -76.63% compared to the previous year's 5.09 million. Losses were -5.95 million, 2.50% more than in 2024.